How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?

Citigroup analyst Geoff Meacham ranks Vertex Pharmaceuticals (VRTX) as a top biotech pick after its $10 billion acquisition of Crinetics. The deal adds endocrinology to Vertex's portfolio, with Citigroup projecting $700M in PALSONIFY sales by 2030. Vertex maintains a Buy rating and $585 price target. The company expects the deal to be accretive to non-GAAP operating income by 2029. Vertex was also added to Bank of America's US 1 List.

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics, adding PALSONIFY and atumelnant with a combined peak revenue potential of over $5B. The deal is expected to be accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes to oversee integration and growth strategies.

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics Pharmaceuticals (CRNX) on September 1, 2026. The deal adds PALSONIFY and atumelnant to Vertex's pipeline, with potential peak revenue of $5B. Vertex also announced leadership changes, including Jonathan Poole's appointment as EVP, CFO in 2027 and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer.

Vertex Pharmaceuticals has completed its $10B acquisition of Crinetics Pharmaceuticals. Jonathan Poole, currently SVP of finance, will become Vertex's CFO in 2027. Charles Wagner, current COO and CFO, will oversee integration. Jasper van Grunsven joins as EVP and chief pain and new product planning officer.